RESUMEN
OBJECTIVE: This study aimed to assess the impact of phenylketonuria (PKU) and its treatment on parent and child health-related quality of life (HRQoL) and to identify the parenting-related correlates of parent and child HRQoL, as well as metabolic control. METHODS: Eighteen mothers of 2- to 12-year-old children with PKU participated and completed a series of self-report questionnaires including the PKU Impact and Treatment Quality of Life Questionnaire (PKU-QOL). RESULTS: Mothers reported that the most significant impact of PKU on HRQoL was in relation to the impact of their child's anxiety during blood tests on their own HRQoL and guilt related to poor adherence to dietary restrictions and supplementation regimens. Higher reported intensity of child emotional and behavioural difficulties and parenting stress were associated with higher scores for PKU symptoms on the PKU-QOL, higher scores for emotional, social, and overall impact of PKU, and higher scores for the impact of dietary restriction. Where mothers reported greater use of overreactivity as a parenting strategy, children tended to have better lifetime phenylalanine levels; however, the overall impact of PKU and the impact of supplement administration on mothers' HRQoL were worse for these families. CONCLUSIONS: These findings have implications for a holistic family-centred approach to the care of children with PKU and their families.
Asunto(s)
Madres/psicología , Responsabilidad Parental/psicología , Fenilcetonurias/psicología , Funcionamiento Psicosocial , Calidad de Vida/psicología , Adulto , Ansiedad/epidemiología , Australia , Niño , Preescolar , Estudios de Cohortes , Femenino , Culpa , Humanos , Masculino , Fenilcetonurias/complicaciones , Fenilcetonurias/terapia , Estrés Psicológico/epidemiología , Encuestas y CuestionariosRESUMEN
Investigations into the biochemical markers associated with executive function (EF) impairment in children with early and continuously treated phenylketonuria (ECT-PKU) remain largely phenylalanine-only focused, despite experimental data showing that a high phenylalanine:tyrosine (phe:tyr) ratio is more strongly associated with EF deficit than phe alone. A high phe:tyr ratio is hypothesized to lead to a reduction in dopamine synthesis within the brain, which in turn results in the development of EF impairment. This paper provides a snapshot of current practice in the monitoring and/or treatment of tyrosine levels in children with PKU, across 12 countries from Australasia, North America and Europe. Tyrosine monitoring in this population has increased over the last 5 years, with over 80% of clinics surveyed reporting routine monitoring of tyrosine levels in infancy alongside phe levels. Twenty-five percent of clinics surveyed reported actively treating/managing tyrosine levels (with supplemental tyrosine above that contained in PKU formulas) to ensure tyrosine levels remain within normal ranges. Anecdotally, supplemental tyrosine has been reported to ameliorate symptoms of both attention deficit hyperactivity disorder and depression in this population. EF assessment of children with ECT-PKU was likewise highly variable, with 50% of clinics surveyed reporting routine assessments of intellectual function. However when function was assessed, test instruments chosen tended towards global measures of IQ prior to school entry, rather than specific assessment of EF development. Further investigation of the role of tyrosine and its relationship with phe and EF development is needed to establish whether routine tyrosine monitoring and increased supplementation is recommended.
Asunto(s)
Suplementos Dietéticos , Fenilcetonurias/sangre , Fenilcetonurias/terapia , Pautas de la Práctica en Medicina , Tirosina/sangre , Tirosina/uso terapéutico , Adolescente , Australasia , Biomarcadores/metabolismo , Niño , Preescolar , Cognición , Suplementos Dietéticos/efectos adversos , Europa (Continente) , Función Ejecutiva , Encuestas de Atención de la Salud , Humanos , Lactante , Recién Nacido , Pruebas de Inteligencia , Pruebas Neuropsicológicas , América del Norte , Fenilalanina/sangre , Fenilcetonurias/diagnóstico , Fenilcetonurias/metabolismo , Fenilcetonurias/psicología , Valor Predictivo de las Pruebas , Encuestas y Cuestionarios , Factores de Tiempo , Resultado del Tratamiento , Tirosina/efectos adversosAsunto(s)
Percepción Auditiva/fisiología , Música , Neurociencias/tendencias , Estimulación Acústica , Adolescente , Corteza Auditiva/fisiología , Niño , Cognición/fisiología , Emociones/fisiología , Humanos , Lactante , Recién Nacido , Memoria/fisiología , Plasticidad Neuronal/fisiología , Discriminación de la Altura Tonal/fisiología , Habla/fisiologíaRESUMEN
PURPOSE OF REVIEW: Seasonal allergic conjunctivitis is a common and clinically significant type I hypersensitivity response, in which the mast cell is considered to play a pivotal role in causing the signs and symptoms, including ocular itching, hyperaemia, lacrimation and chemosis. This review focuses on the biology of the human mast cell, particularly that of the human conjunctiva. RECENT FINDINGS: The ocular mast cell not only releases histamine and eicosanoids into the extravascular environment when activated, but also synthesizes the cytokines IL-4 and TNF-alpha. The number of IL-4 messenger RNA-positive mast cells found in the conjunctival submucosa increases threefold in seasonal allergic conjunctivitis 'in season' compared with 'out of season', suggesting a role in disease. Treatment of the eye with 2% nedocromil sodium eye drops twice a day for 2 weeks reduced the tear concentrations of both histamine and prostaglandin D(2) by more than 70% at 30 min after challenge (both <0.05) illustrating an effective mast cell stabilizing effect in the conjunctiva. SUMMARY: Mast cells are a heterogeneous family of cells that are pivotal in initiating the signs and symptoms of seasonal allergic conjunctivitis. The expression of cytokines also endows them with the ability to initiate the inflammatory cascade, resulting in eosinophil accumulation associated with vernal conjunctivitis. Drug modulation of mast cell activity, although reducing the acute symptoms of active disease, also reduces the cytokine stimulus for the development of chronic allergic inflammation.